A detailed history of Creative Planning transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Creative Planning holds 12,999 shares of NBIX stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,999
Previous 11,573 12.32%
Holding current value
$1.62 Million
Previous $1.59 Million 6.09%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$114.58 - $153.15 $163,391 - $218,391
1,426 Added 12.32%
12,999 $1.5 Million
Q2 2024

Aug 15, 2024

BUY
$130.86 - $143.19 $3,925 - $4,295
30 Added 0.26%
11,573 $1.59 Million
Q1 2024

May 10, 2024

BUY
$130.4 - $143.74 $238,501 - $262,900
1,829 Added 18.83%
11,543 $1.59 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $154,013 - $192,767
1,452 Added 17.57%
9,714 $1.28 Million
Q3 2023

Nov 16, 2023

BUY
$94.02 - $117.1 $79,070 - $98,481
841 Added 11.33%
8,262 $929,000
Q2 2023

Jul 21, 2023

SELL
$89.53 - $104.87 $9,042 - $10,591
-101 Reduced 1.34%
7,421 $699,000
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $66,629 - $87,098
708 Added 10.39%
7,522 $761,000
Q4 2022

Feb 10, 2023

SELL
$106.72 - $127.06 $52,506 - $62,513
-492 Reduced 6.73%
6,814 $813,000
Q3 2022

Nov 03, 2022

BUY
$92.03 - $107.81 $199,152 - $233,300
2,164 Added 42.08%
7,306 $776,000
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $83,520 - $110,277
1,102 Added 27.28%
5,142 $501,000
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $1,159 - $1,516
-16 Reduced 0.39%
4,040 $379,000
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $10,195 - $13,596
128 Added 3.26%
4,056 $345,000
Q3 2021

Nov 10, 2021

BUY
$86.18 - $99.03 $23,958 - $27,530
278 Added 7.62%
3,928 $377,000
Q2 2021

Aug 04, 2021

SELL
$89.43 - $102.27 $23,341 - $26,692
-261 Reduced 6.67%
3,650 $355,000
Q1 2021

Apr 30, 2021

SELL
$87.57 - $119.4 $209,642 - $285,843
-2,394 Reduced 37.97%
3,911 $380,000
Q4 2020

Jan 29, 2021

BUY
$86.91 - $108.33 $24,508 - $30,549
282 Added 4.68%
6,305 $604,000
Q3 2020

Nov 05, 2020

BUY
$96.16 - $135.15 $44,137 - $62,033
459 Added 8.25%
6,023 $579,000
Q2 2020

Jul 23, 2020

BUY
$85.09 - $130.36 $10,636 - $16,295
125 Added 2.3%
5,564 $679,000
Q1 2020

May 05, 2020

SELL
$75.11 - $113.76 $4,431 - $6,711
-59 Reduced 1.07%
5,439 $471,000
Q4 2019

Jan 30, 2020

BUY
$86.8 - $118.57 $18,228 - $24,899
210 Added 3.97%
5,498 $591,000
Q3 2019

Nov 01, 2019

BUY
$83.82 - $101.5 $1,676 - $2,030
20 Added 0.38%
5,288 $477,000
Q2 2019

Jul 26, 2019

SELL
$72.24 - $91.27 $8,307 - $10,496
-115 Reduced 2.14%
5,268 $445,000
Q1 2019

Apr 24, 2019

BUY
$69.31 - $91.53 $4,297 - $5,674
62 Added 1.17%
5,383 $474,000
Q4 2018

Feb 01, 2019

BUY
$68.32 - $124.36 $1,571 - $2,860
23 Added 0.43%
5,321 $380,000
Q3 2018

Oct 25, 2018

BUY
$98.88 - $125.85 $27,686 - $35,238
280 Added 5.58%
5,298 $651,000
Q2 2018

Jul 20, 2018

BUY
$75.3 - $105.99 $2,259 - $3,179
30 Added 0.6%
5,018 $493,000
Q1 2018

Apr 18, 2018

BUY
$75.88 - $92.43 $1,517 - $1,848
20 Added 0.4%
4,988 $414,000
Q4 2017

Jan 17, 2018

SELL
$58.53 - $77.59 $1,170 - $1,551
-20 Reduced 0.4%
4,968 $385,000
Q3 2017

Oct 17, 2017

BUY
$47.97 - $61.28 $239,274 - $305,664
4,988
4,988 $306,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.